Coronavirus epidemic continues in India. Talking about the last 24 hours, there have been 3,29,942 new cases of corona in the country on Tuesday, while 3,876 people have lost their lives due to corona in one day. Meanwhile, India may soon get a good news in the war against Corona. Actually, an expert panel of Covaxin Bharat Biotech of Bharat Biotech has recommended the approval of second and third stage trials for ages 2 to 18 years. According to the official sources, this trial will be done at AIIMS in Delhi and Patna and several other places including the Meditrina Medical Science Institute in Nagpur.
On Tuesday, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) discussed the application of Hyderabad-based Bharat Biotech. The committee has recommended to approve Phase II and Phase III clinical trials on 2 to 18 years of age of Covaxine.
The committee recommended the clinical trial on the condition that along with the submission of the second stage safety data, the DSMB recommendation would have to be presented to the CDSCO before the Phase Three trial.
